Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial.
暂无分享,去创建一个
Wei Zhou | Dirk Schadendorf | Reinhard Dummer | Paolo A Ascierto | Antoni Ribas | Caroline Robert | D. Schadendorf | P. Ascierto | R. Dummer | J. Wolchok | J. Sosman | J. Kirkwood | A. Ribas | F. Hodi | A. Eggermont | C. Blank | I. Puzanov | J. Schachter | A. Daud | A. Pavlick | R. Gonzalez | K. Lewis | C. Robert | S. O’Day | W. Zhou | J. Sosman | C. Loquai | M. Carlino | S. Moschos | O. Hamid | A. Salama | K. Margolin | R. Shapira-Frommer | S. Ebbinghaus | S. Goldinger | S. Hodi | S. Kang | T. Gangadhar | Xiaoyun Li | L. Cranmer | T. Eigentler | S. Agarwala | Jeffrey A Sosman | Alexander Eggermont | Omid Hamid | Rene Gonzalez | April K S Salama | Jedd D Wolchok | Ronnie Shapira-Frommer | Adil Daud | Sanjiv S Agarwala | John M Kirkwood | Carmen Loquai | Adriane M Zernhelt | Igor Puzanov | F Stephen Hodi | Matteo S Carlino | Jacob Schachter | S Peter Kang | Xiaoyun Nicole Li | Anna C Pavlick | Stergios J Moschos | Karl D Lewis | Christian U Blank | Scot Ebbinghaus | Tara C Gangadhar | Steven J O'Day | Kim A Margolin | Simone M Goldinger | J. Lis | Thomas K Eigentler | Lee D Cranmer | Joy Lis | P. Kang | S. Kang | Joy Lis | S. Kang | S. Kang | S. Kang | S. Kang | S. O'Day | April K.S. Salama | Christian U Blank | April K S Salama | Karl D. Lewis | K. Margolin | Thomas Eigentler | J. M. Kirkwood | Thomas K Eigentler | C. U. Blank
[1] Axel Hoos,et al. Guidelines for the Evaluation of Immune Therapy Activity in Solid Tumors: Immune-Related Response Criteria , 2009, Clinical Cancer Research.
[2] Axel Hoos,et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. , 2011, The New England journal of medicine.
[3] T. Okazaki,et al. PD-1 and PD-1 ligands: from discovery to clinical application. , 2007, International immunology.
[4] Drew M. Pardoll,et al. The blockade of immune checkpoints in cancer immunotherapy , 2012, Nature Reviews Cancer.
[5] Antoni Ribas,et al. Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial , 2014, The Lancet.
[6] R. Emerson,et al. PD-1 blockade induces responses by inhibiting adaptive immune resistance , 2014, Nature.
[7] Ryan Emerson,et al. CTLA4 Blockade Broadens the Peripheral T-Cell Receptor Repertoire , 2014, Clinical Cancer Research.
[8] R. Emerson,et al. Distinct immunological mechanisms of CTLA-4 and PD-1 blockade revealed by analyzing TCR usage in blood lymphocytes , 2014, Oncoimmunology.
[9] J. Larkin,et al. Pembrolizumab versus Ipilimumab in Advanced Melanoma. , 2015, The New England journal of medicine.
[10] C. Drake,et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. , 2012, The New England journal of medicine.
[11] A. Ribas,et al. CTLA4 Blockade Induces Frequent Tumor Infiltration by Activated Lymphocytes Regardless of Clinical Responses in Humans , 2011, Clinical Cancer Research.
[12] David C. Smith,et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. , 2012, The New England journal of medicine.
[13] Jason B. Williams,et al. Up-Regulation of PD-L1, IDO, and Tregs in the Melanoma Tumor Microenvironment Is Driven by CD8+ T Cells , 2013, Science Translational Medicine.
[14] Michael Hölzel,et al. Immune cell-poor melanomas benefit from PD-1 blockade after targeted type I IFN activation. , 2014, Cancer discovery.
[15] T. Honjo,et al. PD-L 1 / B 7 H-1 Inhibits the Effector Phase of Tumor Rejection by T Cell Receptor ( TCR ) Transgenic CD 8 T Cells , 2004 .
[16] P. Hegde,et al. MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer , 2014, Nature.
[17] B. Efron. The Efficiency of Cox's Likelihood Function for Censored Data , 1977 .
[18] D. Schadendorf,et al. Nivolumab in previously untreated melanoma without BRAF mutation. , 2015, The New England journal of medicine.
[19] H. Kohrt,et al. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients , 2014, Nature.
[20] Tasuku Honjo,et al. PD-L1/B7H-1 Inhibits the Effector Phase of Tumor Rejection by T Cell Receptor (TCR) Transgenic CD8+ T Cells , 2004, Cancer Research.
[21] Y. Hochberg. A sharper Bonferroni procedure for multiple tests of significance , 1988 .
[22] Antoni Ribas,et al. Improved Survival with T Cell Clonotype Stability After Anti–CTLA-4 Treatment in Cancer Patients , 2014, Science Translational Medicine.
[23] S. H. van der Burg,et al. Anti–CTLA-4 therapy broadens the melanoma-reactive CD8+ T cell response , 2014, Science Translational Medicine.
[24] Alessandro Testori,et al. The role of BRAF V600 mutation in melanoma , 2012, Journal of Translational Medicine.
[25] Antoni Ribas,et al. Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. , 2013, The New England journal of medicine.
[26] A. Ribas,et al. Targeting oncogenic drivers and the immune system in melanoma. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[27] M Nurminen,et al. Comparative analysis of two rates. , 1985, Statistics in medicine.
[28] Yoshiaki Uyama,et al. Moving beyond the hazard ratio in quantifying the between-group difference in survival analysis. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[29] David A. Schoenfeld,et al. Partial residuals for the proportional hazards regression model , 1982 .
[30] D. Schadendorf,et al. Improved survival with ipilimumab in patients with metastatic melanoma. , 2010, The New England journal of medicine.
[31] G. Linette,et al. Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial. , 2015, The Lancet. Oncology.